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The low eﬃciency observed in cloning by nuclear transfer is related to an aberrant gene expression following errors in epigenetic
reprogramming. Recent studies have focused on further understanding of the modiﬁcations that take place in the chromatin
of embryos during the preimplantation period, through the use of chromatin modifying agents. The goal of these studies is to
identify the factors involved in nuclear reprogramming and to adjust in vitro manipulations in order to better mimic in vivo
conditions. Therefore, proper knowledge of epigenetic reprogramming is necessary to prevent possible epigenetic errors and to
improve eﬃciency and the use of in vitro fertilization and cloning technologies in cattle and other species.
1.Introduction
Despite being utilized for nearly three decades [1], the
production of embryos in vitro still has limitations, such as,
lower eﬃciency when compared to in vivo production. In
bovine oocytes, matured and fertilized in vitro, high cleavage
rates are currently obtained. However, only 25%–40% of
these zygotes are capable of progressing to the blastocyst
stage [2]. Recent studies suggest that epigenetic alterations
and consequent changes to chromatin conformation may
take place during in vitro culture [3]. Enright et al. [4]
reportedelevatedlevelsofhistoneH3andH4acetylationfol-
lowing long-term culture of embryos. Furthermore, in vitro
produced bovine embryos showed altered gene expression
patterns when compared to in vivo controls [5].
In somatic cell nuclear transfer (SCNT), perturbations
in epigenetic patterning are also thought to play a role in
the low eﬃcacy seen following the use of this technology. In
SCNT, the nucleus of a diﬀerentiated adult somatic cell is
reprogrammed by factors in the oocyte cytoplasm in order
to regain the pluripotent patterns of an embryonic cell [6–9].
However, failure in this nuclear reprogramming [10, 11],
resulting in abnormal epigenetic patterns in cloned embryos,
has been reported [12]. Furthermore, development to the
blastocyst stage and survival to birth are signiﬁcantly lower
in clones in comparison to embryos produced by in vitro
fertilization [11–14]. In cloned mice, animals do not appear
to pass an abnormal trait on to their oﬀspring produced
in vivo. This may suggest that a perturbation to proper
epigenetic patterning, rather than to genetic sequences,
is responsible of the aberrant phenotypes and also of the
low eﬃciency seen following the use of this technology
[15].
In view of these concerns following the use of in vitro
technologies for the production of embryos, recent studies
aim at understanding the chromatin structure modiﬁcations
during preimplantation and the improvement of in vitro
approaches to most closely mimic the in vivo changes that
allow the growth and survival of embryos. In the present
paper, we will discuss some of the epigenetic mechanisms
involved in embryo development and the use of treatments
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2. Mechanisms of EpigeneticRegulation
Epigenetic refers to the control of gene function and expres-
sion without changes to the gene sequence. Such control
allows for diﬀerent expression patterns, from an identical
genome sequence, to take place in separate cells or tissues,
establishing the basis for tissue-speciﬁc gene expression
[16].
Epigenetic modiﬁcations control gene expression by a
variety of processes which include DNA methylation, post-
translational histone modiﬁcations, noncoding RNAs [17].
The processes of DNA methylation and histone modiﬁcation
have gained great interest in the ﬁelds of mammalian
development [16]. We will further discuss these studies and
how they may oﬀer insight into the production of embryos
in vitro.
2.1. DNA Methylation. DNA methylation is one of the
most well-described epigenetic mechanisms and plays a key
role in several biological processes such as, transcriptional
regulation, chromosomal organization, X-inactivation, and
genomic imprinting [18–22]. A family of DNA (cytosine-5)-
methyltransferases (DNMT) is responsible for the addition
ofamethylgrouptothe5thpositionofthecytosinering,and
ﬁve DNMTs have been already characterized in mammals:
DNMT1, 2, 3A, 3B, and 3L [23]. DNMT1 is responsible for
the maintenance of methylation through the remethylation
of new strands during replication if the mother strand was
also methylated [22]. The DNMT3 enzymes (DNMT3a,
3b, and 3L) are involved in the acquisition of de novo
methylation on DNA previously devoid of methylation [24].
Loss of methylation patterns through genetic ablation of
these enzymes is lethal at early embryonic or postnatal stages
in mice [24, 25].
Amongst all the biological processes involving DNA
methylation, genomic imprinting is one of the most
intriguing, as it involves the formation of an epigenetic
“mark” at certain loci in a parent-of-origin-speciﬁc manner
such that genes are expressed monoallelically [26]. Biallelic
expression or silencing of imprinted genes is detrimental to
fetal growth, phenotype, and survival, considering that the
accurate maintenance of inherited methylation patterns on
imprinted genes in preimplantation is critically important
for the success of both in vivo and in vitro embryonic
developments.
PatternsofDNAmethylationareerasedintheprimordial
germ cells during embryonic life and re-established in
a sex-speciﬁc manner in the gametes during germ cell
development. However, for the purpose of the review, we
will discuss another important wave of demethylation that
occurspostfertilization.Genome-widemethylationiserased,
except for methylation of imprint genes and certain repeat
sequences, with reacquisition of methylation in mice taking
place during the peri-implantation stage in the expanded
blastocyst (review in [26]).
2.2. Histone Modiﬁcations. Another important epigenetic
process is histone modiﬁcation. Histones are proteins bound
to DNA forming the highly conserved structural polymer
known as chromatin. Nucleosomes are the fundamental
repeating units of chromatin. A nucleosome consists of
146-base pairs of DNA wrapped around a core of histone
proteins. The histone proteins that make up this core are 2
copies each of H2A, H2B, H3, and H4. A linker histone, H1,
is bound to the DNA between nucleosomes, allowing for the
solenoid helical ﬁber structure of DNA in the nucleus. These
core histones are highly conserved across species. Histone
proteins havea globularcarboxy-terminal domain that binds
the DNA and a ﬂexible amino-terminal tail that extends
out of the nucleosome structure. Modiﬁcations of histones
occur on amino residues, primarily on the amino-terminal
tail (reviewed in [27]). These covalent modiﬁcations have
fundamental functions on chromatin condensation, DNA
replication, DNA repair, and gene regulation. Depending on
the type of modiﬁcation that occurs, the nucleosome will
either open up to allow for transcriptional factors to bind or
remain tightly wound.
Histone acetylation is commonly associated with acti-
vated transcription, whereas deacetylation is associated with
transcriptional repression [27–29]. Research has shown that
acetylation of histone H4 is reduced on the inactive X
chromosome in female mammals, suggesting that absence
of acetyl groups is be a prerequisite for a more condensed
and inactive chromatin stage [30]. Histone amino groups
can also be methylated, phosphorylated, and ubiquitinated
[27, 31].
Examples of some modiﬁcations that are commonly
associated with euchromatin, regulating gene expression are
acetylationofhistoneH3andH4,aswellasdi-andtrimethy-
lation of lysine 4 on histone H3 [31]. The region of DNA
on the chromosome that is constitutively silenced (telomere,
centromeres, and heterochromatin) is hypoacetylated [31–
33]. In addition, these regions are highly methylated on
particular amino acid residues (lysine 9 and lysine 27 of
histone H3) [31, 34]. Among the histone modiﬁcations,
acetylation and methylation have been the most studied.
Unlike histone acetylation, histone methylation is more
complex, with gene expression being aﬀected diﬀerently
depending on which residue is modiﬁed [35]. Loci-speciﬁc
modiﬁcations of histones, and the combination of these
modiﬁcations, have been described as a “histone code”
that deﬁnes the state of a cell’s transcriptional potential
[36].
Several enzymes have been reported to control histone
modiﬁcation. Two proteins involved with controlling the
acetyl groups are histone acetyltransferase (HAT; adds
acetyl groups) and histone deacetylase (HDAC; removes
acetyls groups) [37]. Several of these enzymes (HDACs 1,
2, 3, 7, and HAT1) have been detected in bovine embryos
[38]. As more research is conducted, it becomes apparent
that crosstalk between enzymes is a common feature. For
example in Schizsaccharomyces pombe, HDAC is required
for deacetylating the histone 3 lysine 9 residue in order for
histone methyltransferase to act on that particular residue
[34]. The HAT enzymes not only aﬀect chromatin, but
also act as coactivators on certain transcription factors
[39]. Interactions also occur between HDACs and DNMTs
[40–42].Veterinary Medicine International 3
3.EpigeneticModiﬁcations in
Mammalian Embryos
Embryonic development involves a wide array of epigenetic
modiﬁcations, including DNA methylation and histone
modiﬁcations, which are fundamental for genomic imprint-
ing and X-chromosome inactivation in female embryos [43].
In mammals, levels of histone methylation are higher and
histone acetylation levels are lower in male gametes com-
pared to female gametes [12, 44–47], resulting in minimal
gene expression at this stage.
During normal bovine embryo development, histone
demethylation occurs soon after fertilization [12]. Histone
methylation is reduced in 2 to 4 cell embryos, and starts to
increase at the 8- to 16- cell stage, concurrently with zygotic
genome activation [48]. Histone acetylation levels peak at
the time of zygotic genome activation, corresponding to the
time of increased gene expression, then diminish during the
morula stage [49]. The ﬁrst cellular diﬀerentiation of the
developing embryo occurs at the blastocyst stage giving rise
to the inner cell mass (ICM) and trophectoderm [48]. At the
blastocyst stage, DNA and histone methylation is elevated
in the ICM, whereas DNA and histones are hypomethylated
in the trophectoderm. Thus, blastocyst formation establishes
the beginning of epigenetic diﬀerences between the two cell
lineages [50].
Another important event in normal mammalian embryo
development is X-chromosome inactivation (XCI). Gene
expression from one X chromosome is suﬃcient to allow for
normal embryonic development, as seen in male embryos
[51]. Therefore, in female embryos, the extra X chromosome
must be silenced [12]. Establishment and maintenance of
XCI are regulated by epigenetic mechanisms. Research has
shown XCI imprinting in the bovine [52] and murine
[53, 54] placentas. In mice, imprinting of XCI occurs
during preimplantation development, with the paternal
chromosome preferentially silenced [52–54]. The paternal
X chromosome is silenced at the 4-cell stage, shortly after
zygotic genome activation [55]. This pattern persists in the
trophectodermlinage,wheretheactiveXchromosomeinthe
placenta is of maternal origin. However, in the ICM of devel-
opingembryo,thepaternalXchromosomeisreactivatedand
forthwith both maternal and paternal X chromosomes are
randomly selected for inactivation [55, 56].
Regards to DNA methylation, during the early postfertil-
ization stages there is an intense wave of DNA demethylation
in both pronuclei, albeit at diﬀerent speeds, followed by a
global remethylation that takes place at peri-implantation
stages in the mouse. Further, not all sequences have their
methylation patterns removed, as this is the case for
imprinted sequences, which maintain their methylation
marks throughout life except in the germ cell line [43].
3.1. Epigenetic Modiﬁcations in Cloned Embryos. In cloning
by somatic cell nuclear transfer, the epigenetic patterns of
the adult somatic cell must be erased and reprogrammed to
thoseofatotipotentembryoniccell.Duringthedevelopment
of embryos in vivo, patterns carried by both gametes are
eachreprogrammedinaveryspeciﬁcandtimelymannerand
embryonic patterns of the totipotent cell must be established
to support the embryonic genome activation that ensues
[57–59]. Failure is the re-establishment of correct epigenetic
marks that can aﬀect totipotency and proper diﬀerentiation
and development of embryos [60, 61]. Initial epigenetic
patterns of the adult somatic cell used for cloning can
aﬀect reprogramming following nuclear transfer [62]. In
fact, diﬀerences in embryo development have been described
following the use of cells of diﬀerent tissue origins for SCNT
[63–65].
Several studies have demonstrated abnormal DNA and
histone methylation patterns in SCNT bovine embryos
compared with in vivo and in vitro produced embryos [43,
48, 66–68]. Also, global transcriptome proﬁle experiments
revealed down regulation of genes involved in chromatin
remodeling in cloned embryos compared with in vitro
fertilized embryos [69].
As mentioned above, early embryos present an intense
and very well-orchestrated reprogramming of DNA methy-
lation, and questions arise as to whether the nucleus of the
donor cell in SCNT embryos, carrying a somatic cell pattern
of methylation, can be manipulated in order to mimic this
intense reprogramming taking place during early embryonic
stages [43]. Unlike normal embryos, SCNT embryos have
incomplete demethylation after the one cell stage, regardless
of species [43]. In addition, these SCNT embryos started
to undergo de novo methylation prematurely (4-cell stage
versus 8- to 16- cell stage for in vivo embryos), so by the
morula stage, methylation in the blastomeres resembled that
of the donor cells [43]. The methylation status of ICM
in SCNT bovine blastocysts is similar to in vivo blastocyst
embryos. However, the trophectoderm of SCNT blastocsyts
isabnormallyhypermethylated[12,43].Thesechangesinthe
normal timing of methylation result in potentially serious
consequences in epigenetic reprogramming and further
development of the trophectoderm, turning mammalian
cloning to an impractical reproductive technology until the
timing of events taking place during in vitro production can
be controlled by scientists [70].
In addition to abnormal DNA methylation, histone
modiﬁcations are also altered in SCNT embryos. San-
tos and coauthors [48] demonstrated that SCNT bovine
embryos had hypermethylation histone H3-K9 associated
with genome-wide hypermethylation. A study also reported
that acetylation of lysine 5 on histone H4 (H4-K5ac) appears
to change dramatically during early embryo development of
IVF produced embryos, but remains consistently elevated
in SCNT produced bovine embryos [71]. Compared to
in vitro fertilized embryos, SCNT bovine embryos have
elevated heterochromatic histone methylation (H3K9me2)
and H3K9-acetylation in the trophectoderm layer [48].
These and other modiﬁcations could explain the altered
expressionofvitaldevelopmentalgeneslaterindevelopment.
Another complication with nuclear transfer is the repro-
gramming of imprinted genes. Abnormalities generally asso-
ciated with cloned animals resemble those observed in mice
with imprinted gene mutations [72]. Analysis of bovine H19
demonstratedthatSCNTanimalsthatdiedshortlyafterbirth
had biallelic expression [73]. The placenta of SCNT animals4 Veterinary Medicine International
appearstobeespeciallyvulnerabletoabnormalexpressionof
imprinted genes [12]. Inoue et al. [74] observed abnormally
lowlevelsofexpressionofboth imprinted andnonimprinted
genes in the placentas of SCNT mice, whereas expression
in the embryo was not altered. Similarly, Yang et al. [75]
observed abnormal expression of the imprinted gene IGF2R
in the placenta but not in the organs of SCNT calves. Smith
et al. [76] found reduced expression of the placenta-speciﬁc
gene Cd81 between SCNT and in vivo bovine blastocysts.
In early pregnancy, expression of the imprinted placental
genes Ascl2 has been shown to be altered in SCNT bovine
embryos and placental tissues [77]. In SCNT embryos, Ascl2
was overexpressed.
Nuclear reprogramming also aﬀects X chromosome
inactivation, particularly in the placenta. Reports have
shown that the ICM of SCNT embryos had normal XCI
(i.e., random paternal/maternal inactivation), whereas the
placenta had altered gene expression from X-linked genes
[12]. However, in day 8 blastocysts, Smith et al. [76]f o u n d
no evidence of abnormal expression of X-linked genes from
SCNT bovine embryos. It must be noted that complete XCI
in bovine embryos has been reported to occur at day 14-
15 [78]. At later stages, reports of bi-allelic expression of X-
linked genes in the placenta of deceased clones indicate the
absence of the paternal XCI that is observed in non-SCNT
calves [52]. Live SCNT calves had one active X-chromosome,
similar to non-SCNT calves, suggesting that abnormal XCI
could contribute to fetal loss [52].
These results provide further evidence towards the
incomplete epigenetic reprogramming of SCNT embryos
and the trophectoderm cell lineages appear to be highly
vulnerable to these defects.
4. The Use of Histone Deacetylase Inhibitors for
In Vitro Production of Bovine Embryos
The ﬁrst reports of utilizing HDAC inhibitors were in cancer
therapies. Inhibitors of HDAC promote global chromatin
acetylation, which leads to excessive gene transcription. This
increase in protein production in tumor cells would induce
cellular diﬀerentiation, modifying their characteristics of
excessive cell growth [79]. Inhibitors of HDAC have been
reported to have antiproliferative and apoptotic eﬀects,
which are beneﬁcial in cancer therapies. Mutation of the
HDAC1 gene in mice caused reduced cell proliferation which
led to the embryonic death at midgestation [80]. These
eﬀects were associated with increased gene expression of
cell cycle inhibitors [80]. Similar antiproliferative eﬀects
were seen in embryonic stem cells [81, 82]. Crystallography
studies indicated that these inhibitors act by binding the
catalytic site of the enzymes, blocking therefore the access
to the substrates [83]. Among the known inhibitors, some
of the most used are (I) trichostatin A, (II) valproic acid,
clinically used in the treatment of epilepsy, and (III) sodium
butyrate [84]. These substances cause reversible inhibition of
the majority of class I and II HDACs [85].
To improve SCNT eﬃciency, researchers have turned to
stimulating donor cell reprogramming by chemical treat-
ments. Donor cells treated with trichostatin A (TSA) have
been shown to have a slight improvement on the develop-
ment of cloned embryos in cows [10, 62, 86, 87], mice [49,
88–90], pigs [91–95], and rabbits [96, 97]. In pigs, live births
were reported following TSA treatment [92, 95]; in rabbits,
however, there was no survival of oﬀspring to adulthood
[97]. In the bovine, both treatments of donor cells [4, 10, 86]
or of the reconstructed embryos [10, 87] were beneﬁcial
to the development of clones. The type of donor cell also
appears to have a role on the beneﬁts of TSA treatment.
In mice, blastocyst formation was 5-fold higher in embryos
treated with TSA that were produced from cumulus cells
[88]. However, TSA had no eﬀect on blastocyst development
from embryos produced by embryonic stem cells. These
results suggest that inhibition of HDAC is only beneﬁcial in
donor cells that are more diﬀerentiated [88]. Similar results
also suggest that hypoacetylation may be a limiting factor in
the development of cloned embryos [96, 98].
It is thought that TSA aids nuclear reprogramming and
subsequently improves expression of embryonic genes such
as, Nanog [87], SOX2, and cMyc [90], and regulates expres-
sionofgenesrelatedtochromatinstructureandDNAmethy-
lation[90].Furthermore,theuseofTSAimprovesderivation
of embryonic stem cell lines from cloned embryos [88].
TheuseofgeneralHDACinhibitorsaﬀectsallchromatin,
which may have negative eﬀects when utilized at elevated
concentrations for extended periods of time. Tsuji et al. [89]
demonstrated that the beneﬁcial eﬀects of TSA treatment on
cloned embryos declined after 12 hours, leading to reduced
blastocyst formation and fetal loss. Li et al. [92]r e p o r t e d
that in pigs, cloned embryos treated with TSA had a 15-hour
delay to reach the stage of compacted morula. Furthermore,
embryos fertilized in vitro had elevated apoptotic levels fol-
lowing TSA treatment [99]. Apoptosis, or programmed cell
death, is a physiological event that has been associated with
reduced viability and death of bovine embryos [100, 101].
TSA has been shown to induce expression of proapoptotic
genes [102] and, by facilitating histone hyperacetylation,
allows the DNA to be available for endonucleases [103].
The addition of TSA, during fertilization, promoted
increasedlevelsofhistoneacetylationonthesperm.Cleavage
rate and blastocyst formation were not altered. However,
there were more cells in the ICM of embryos that received
TSA during fertilization [104]. These results suggest that
alteration of histone acetylation during fertilization aﬀects
subsequent cell proliferation and diﬀerentiation [104].
Embryos cultured with TSA after fertilization, in an eﬀort
to aid the activation of embryo genome, had increased levels
of histone acetylation, but blastocyst development was not
aﬀected [99]. Higher levels of apoptosis were seen in high
quality embryos but not in the lower quality ones, suggesting
that the use of TSA can beneﬁt this group of embryos.
Further, they reported gender diﬀerences in the response
to histone hyperacetylation following TSA treatment, with
female embryos being more sensitive than males [99]. Future
studies are warranted to investigate gene expression patterns
in embryos following TSA treatment in order to further
evaluate potential eﬀects of this agent in early embryo
development.Veterinary Medicine International 5
Other HDAC inhibitors are currently being investigated
for the use in nuclear transfer in pigs: valproic acid, which
resulted in higher levels of Oct4 expression [105]a n d
scriptaid [94] and sodium butyrate [106], which resulted in
cloned embryos with acetylation levels similar to fertilized in
vitro. However, special attention must be paid to the fact that
the use of valproic acid as an antiepiletic drug (AED) in the
ﬁrst trimester of pregnancy was associated with signiﬁcantly
increased risks of several congenital malformations [107].
Antiepileptic drugs in general are related to malformations,
and it is probable that they aﬀect development through
multiple mecanisms [108]. Valproic acid has been shown to
disrupt the Wnt signalling pathway. However, valproic acid
analogues that do not alter Wnt signalling, do not produce
teratogenic eﬀects. Other main mechanisms have been con-
nected to valproic acid teratogenic eﬀects, such as, inhibition
of folate metabolism and neural apoptosis induction [108],
and recent studies reveal HDAC inhibition as one of the pos-
sible mechanisms for valproic acid teratogenic eﬀects [109].
In this respect, experiments involving HDAC inhibitors
supplementation must be aimed to use the minimum
working concentration, in order to inhibit minimum HDAC
and obtain the desired eﬀect. Even though the dosages
applied for embryo culture are lower for trichostatin A,
whichis supplementedatnanomolar concentrations,further
studies accessing teratogenic eﬀects of this and others HDAC
inhibitors are needed.
5. Use of DNA MethylationInhibitors
As mentioned earlier, several studies indicated that aberrant
epigenetic reprogramming occurs in cloned embryos [60,
66, 68]. Partial demethylation and early methylation, at the
four-toeight-cellstageinclonedembryos[110],indicatethe
presence of inadequate nuclear reprogramming in regards to
DNA methylation [43].
Researchers aimed at preventing DNA hypermethylation
in animal cloning through the use of methylation inhibitors.
PretreatmentofdonorcellswithaninhibitorofDNAmethy-
lation, 5-aza-2-deoxycytidine (5-aza-Dc), before nuclear
transfer does not appear to improve development of cloned
embryos [111, 112]. These results may indicate that inhibi-
tion of excess methylation alone fails to aid reprogramming
in the donor cell nucleus, as erasure and reacquisition of
methylation during the preimplantation period in embryos
is a very complex procedure and may require the use of a
combination of agents to try and mimic this process in vitro.
6. Conclusions andFutureDirections
As discussed here and in the work of others, somatic patterns
of histone modiﬁcations, as well as DNA methylation,
present in diﬀerentiated adult cells, must be erased and
reprogrammed in a highly organized and timely manner.
The acquisition of unique embryonic epigenetic marks must
take place in cloned embryos in a similar manner as seen
following erasure and acquisition of epigenetic marks in the
female and male pronuclei. Failure during erasure and/or
acquisition of these marks will aﬀect subsequent embryonic
development [60, 61].
Current studies aim at (1) understanding the factors
involved in nuclear reprogramming, (2) identifying possible
failures in reprogramming induced by cell manipulation
and/or culture conditions, and (3) utilize inhibitors and
other agents that could assist in the establishment of proper
epigenetic patterning during early embryo development. All
these eﬀorts to elucidate the complex steps of epigenetic
reprogramming during embryogenesis, as well as how to
manipulate these steps, are necessary to improve the eﬃ-
ciency and applicability of in vitro production of embryos
and cloning.
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